Skip to content

Addiction: all studies

Page 14 of 857: studies 131 to 140 of 8,563, newest first. Back to the addiction overview

Research

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.

Brain Sciences September 28, 2025 Sabrina Correa Da Costa, Nicholas L. Bormann, Tyler Oesterle et al. 3 citations

Background: Substance use disorders (SUDs) are highly prevalent, affecting over 48.5 million Americans. Available treatments for SUD remain insufficient, and many patients do not respond to existing interventions despite adequate adherence to treatments. While novel therapies for SUD are urgently needed, the use of psychedelic drugs for the treatment of SUDs has shown promise. Objectives: This...

DOI: 10.3390/brainsci15101056 (opens in new tab) Full text (opens in new tab) Psychedelics Addiction treatment Substance use disorders Therapeutic research

Co-Boost: boosting and guiding neuroplasticity by combining ketamine with neurofeedback-assisted learning—towards an individualised and integrated pharmaco-psychotherapy for cocaine addiction: study protocol for a randomised, placebo-controlled, double-blind, parallel-group, single-centre trial

Trials September 25, 2025 Anna Trippel, Ladina P Gubser, Etna Engeli et al. 1 citation

BACKGROUND: Cocaine is the most frequently used stimulant worldwide, with increasing consumption rates in Europe. Cocaine use is associated with great harm to individuals and society. As of today, psychotherapeutic interventions for cocaine use disorder (CUD) demonstrate only modest effect sizes, and no pharmacotherapy has been approved due to gaps in understanding the disease. However, a novel...

DOI: 10.1186/s13063-025-08982-9 (opens in new tab) Ketamine Neuroplasticity Boosting machine learning Protocol science +5

Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.

Brain Sciences September 12, 2025 Krista Ulisse, Jehad Albitar, Jourdan Aromin et al. 5 citations

Addiction remains a persistent public health crisis, marked by poor treatment retention and limited pharmacotherapy options. Emerging treatments, such as psychedelic-assisted psychotherapy and neuromodulation, offer promising avenues for circuit-level interventions in behavioral addictions. This narrative review synthesizes the current landscape of psychedelic compounds and neuromodulation...

DOI: 10.3390/brainsci15090980 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelics & neuromodulation Brain stimulation Novel treatments +17

Mindfulness-Oriented Recovery Enhancement Reduces Illicit Substance Craving Among People with Alcohol Use Disorder and Polysubstance Use.

Substance Use & Misuse September 2, 2025 Laura Gurrieri, Margaret C. Wardle, Eric L Garland

Background: Polysubstance use is common in alcohol use disorder (AUD) and associated with poor treatment outcomes. Cannabis and cocaine often co-used with alcohol, have no approved medication treatments and respond poorly to common behavioral treatments. Thus, treatments that can reduce use of these substances alongside AUD are critically needed. Objectives: We tested whether...

Psychedelics for substance use disorders: are women being addressed? A scoping review

International Journal of Drug Policy September 2, 2025 Alexandra Wojdyslawski Nigri, Ilana Falcão de Arruda, Catarina Maia et al. 3 citations

INTRODUCTION: Substance use disorders (SUDs) are a prevalent health issue that affects individuals globally. Research is currently being conducted on the potential use of psychedelics as a new approach to treating SUDs. Women have been shown to respond differently than men to SUDs treatments and women-specific approaches have been recommended. This scoping review explores the ways in which...

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology September 2, 2025 Lucas M Wittenkeller, Gary A. Gudelsky, Theresa Winhusen et al. 3 citations

Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed...

Targeting Internet Addiction Through Body Awareness Psychotherapy: The Mediating Role of Executive Functions and Emotion Regulation.

Brain and Behavior September 1, 2025 Maliheh Fallah, Hamidreza Mohajerani, Abdullah Omidi et al.

Internet addiction disorder (IAD) is increasingly recognized as a behavioral addiction linked to deficits in executive functioning, emotion regulation, boredom susceptibility, and impaired time perception. Emerging therapies such as body awareness psychotherapy (BAP) aim to improve cognitive and emotional self-regulation through embodied mindfulness. This study aimed to assess the effectiveness...

DOI: 10.1002/brb3.70846 (opens in new tab) Full text (opens in new tab) Body awareness psychotherapy Cognitive function Emotion regulation Internet addiction +1

Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review.

NeuroSci August 27, 2025 Alexander Thomas, R Andrew Chambers 4 citations

Interest in ketamine as a novel treatment for substance use disorders (SUDs) has been increasing due to its N-methyl-D-aspartate (NMDA) glutamate receptor antagonism and mounting evidence that glutamate neurotransmission is involved in the pathogenesis of both depression and addictions. This narrative review provides an outline of clinical evidence reported in the literature from the 1970s to...

DOI: 10.3390/neurosci6030083 (opens in new tab) Full text (opens in new tab) Ketamine Nmda n-methyl-d-aspartate Case reports Cohort studies +3

Reconsidering Ibogaine for the treatment of severe mental illness and substance use disorders

Journal of Medicine Surgery and Public Health August 25, 2025 R. Andrew Yockey 2 citations

Severe mental illness (SMI) and co-occurring substance use disorders (SUDs) continue to pose a major global health challenge, contributing to high rates of mortality, disability, and economic strain. Ibogaine, a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, has shown promise in easing withdrawal symptoms, reducing cravings, and improving psychiatric...

DOI: 10.1016/j.glmedi.2025.100213 (opens in new tab) Mental illness Substance use Psychotherapist Mental health

Effect of Sookshma Meditation on Internet Addiction, Emotional Regulation, and Mindfulness in School Children: A Randomized Controlled Trial

Indian Journal of Science and Technology August 23, 2025 Chanchal Surywanshi, Ashween Bilagi, Meghnath Verma et al.

Objectives: To determine the effect of Sookshma Meditation (SM) on Internet Addiction (IA), Emotional Regulation (ER), and Mindfulness in School Children- A randomized controlled trial. Methods: A randomized control trial designed to assess the effect of SM (Meditation-based Yoga practices) on IA, ER, and Mindfulness in school-going children. After screening, 80 school-going children (44 boys &...